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ASBMT Best Abstract Awards 
for Outstanding Basic Science Research
Each year the American Society for Blood and Marrow Transplantation presents Best Abstract Awards to recognize
outstanding research in the basic sciences that contribute to the advancement of the field of blood and marrow
transplantation. The abstracts receiving the award are those that were scored highest by the Abstract Review
Committee. Each award is accompanied by a prize of $1,000. The awards are supported by an unrestricted educational
grant from Roche Laboratories.
4
IL-7 ENHANCES T CELL RECONSTITUTION AFTER ALLO BMT
THROUGH INTRATHYMIC AND EXTRATHYMIC MECHANISMS
Alpdogan, O.; Schmaltz, C.; Muriglan, S.J.; Kappel, B.J.;
Greenberg, A.S.; Willis, L.; Kirovski, A.; Rotolo, J.A.; Halm, J.A.;
van den Brink, M.R. Memorial Sloan-kettering Cancer Center, New
York, NY
We used murine models for MHC-matched and -mismatched
allo BMT with young (3-month old) and middle-aged (9-month
old) recipients to study immune reconstitution. We found that T
cell reconstitution, in contrast to myeloid, erythroid, and B cell
recovery, was not completed at 12 weeks post allo BMT. Thymic
output was dependent on MHC differences, the occurrence of
GVHD and the age of recipients. We observed that most donor T
cells during reconstitution had a memory T cell phenotype. How-
ever we demonstrated by in vivo BrdU labeling that a subpopula-
tion of these cells in time will revert to naïve T cell phenotype.
Administration of Interleukin-7 (IL-7) to allo BMT recipients could
enhance thymopoiesis and peripheral B and T cell numbers inde-
pendent of MHC differences or age of the recipient. We found that
apoptosis in peripheral CD4+ T in middle-aged allo BMT recipi-
ents was increased and was associated with a decrease in intracellu-
lar Bcl-2 expression and intensity. IL-7 administration could
enhance Bcl-2 levels in CD4+ T cells and decrease the percentage
of apoptotic cells. In contrast, IL-7 had no effect on the percentage
of apoptotic CD8+ T cells. Upon cell cycle analysis we found an
increase of peripheral T cells in S phase after IL-7 administration to
allo BMT recipients. Analysis by CFSE labeling demonstrated that
alloreactive T cells downregulate their IL-7Rα upon activation,
which suggest that they become insensitive to IL-7 stimulation dur-
ing GVHD. In contrast, IL-7Rα expression is upregulated during
homeostatic expansion on T cells in recipients of syngeneic BMT.
In conclusion, IL-7 is a potent lymphopoietic growth factor in allo
BMT recipients through its effects on thymopoiesis, peripheral T
cell expansion and apoptosis without aggravating GVHD.
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PEPTIDE-LOADED EBV TRANSFORMED B CELLS ARE EFFECTIVE
ANTIGEN PRESENTING CELLS FOR RAPID IN VITRO GENERATION OF
HLA-RESTRICTED WT-1 SPECIFIC CYTOTOXIC T CELLS FOR
ANTILEUKEMIA ADOPTIVE CELL THERAPY
Doubrovina, E.S.; Lee, S.; Koehne, G.; Doubrovin, M.; Guerrero, J.;
Daiz-Barrientos, T.; O’Reilly, R. MSKCC, New York, NY
The Wilm’s tumor protein WT-1 is highly expressed in most
acute or chronic leukemias and can be recognized by cytotoxic T
lymphocytes (CTLs). We examined the feasibility of in vitro gener-
ation of WT-1 speciﬁc CTLs by stimulation with autologous pep-
tide-loaded EBV transformed B cells (BLCL/WT-1) as antigen
presenting cells in comparison to adherent monocytes (MON/WT-
1) using two WT-1 HLA-A*0201 binding peptides (RMFPNAPYL
or SLGEQQYSV). NK-cell- and monocyte-depleted peripheral
blood lymphocytes from two healthy HLA-A*0201+ donors were
stimulated in vitro with the irradiated BLCL/WT-1 or
MON/WT-1 and cultured in the presence of IL-2 for 27 days. The
CTLs stimulated with BLCL/WT-1 contained a higher proportion
of CD8 positive cells in comparison to monocyte-stimulated cul-
tures (65% vs. 8% respectively). Unlike the MON/WT-1, the
BLCL/WT-1 cells also stimulated a large number of EBV-speciﬁc
CTls. However, the fraction of WT-1 speciﬁc CTLs was higher in
cultures sensitized with BLCL/WT-1 than with MON/WT-1, as
quantitated by T cell binding with the HLA-A*0201/WT-1 peptide
tetramers (3.3% vs 0.5% respectively) or by the production of intra-
cellular IFN-gamma in response to peptide-speciﬁc stimulation. In
addition, total yield of WT-1 peptide-speciﬁc CTLs was 40 fold
higher following sensitization with BLCL/WT-1 as compared to
MON/WT-1. The WT-1-speciﬁc T cells from both types of cul-
ture lysed HLA-A*0201+ fresh WT-1+ leukemia cells as well as
peptide loaded HLA-A*0201+ targets, but not WT-1-negative
HLA-A*0201+ targets or HLA mismatched targets loaded with the
relevant WT-1 peptide. These cells also failed to lyse WT-1-nega-
tive autologous PHA stimulated blasts or PHA stimulated blasts
from HLA matched A0201+ allogeneic leukemic hosts.
BLCL/WT-1 sensitized CTLs also significantly inhibited the
growth of HLA-A*0201+/WT-1+ primary leukemic xenografts in
SCID mice. This approach thus permits rapid in vitro generation of
large numbers of HLA-restricted WT-1 peptide-speciﬁc T cells for
adoptive cell therapy of WT-1+ leukemias.
6
DISRUPTION OF THE INNATE IMMUNE RESPONSE BY TARGETING
CD14:LPS INTERACTIONS REDUCES GVHD AND PRESERVES GVL
AFTER EXPERIMENTAL ALLOGENEIC BMT
Cooke, K.R.1; Olkiewicz, K.1; Erickson, N.1; Clouthier, S.1;
Liu, C.2; Ferrara, J.L.1 1. University of Michigan Cancer Center,
Ann Arbor, MI; 2. University of Florida College of Medicine,
Gainsville, FL
Acute GVHD fundamentally depends upon adaptive immunity
and interactions between donor derived T cells and foreign host
tissue antigens. Recent studies have also demonstrated an impor-
tant role for endogenous LPS in the induction of GVHD. CD14 is
the principle receptor for LPS and is critical component of the
innate immune response. We evaluated the role of CD14 in the
development of GVHD by using P → F1 mouse BMT models.
Lethally irradiated F1 mice received allo BMT from either wild
type (wt) or CD14 -/- parental donors or syngeneic (F1) BMT. Allo
BMT with CD14 -/- donors resulted in signiﬁcantly reduced mor-
tality from GVHD through day +42 compared to wt donors. This
observation was associated with a significant decrease in serum
TNFα levels and intestinal histopathology (day +7) and improved
clinical scores (as measured by alterations in weight, skin integrity,
fur texture, mobility and posture) of surviving animals. BMT with
CD14 -/- cells had no effect on donor T cell responses to host anti-
gens in vivo (serum IFNγ levels and donor T cell expansion), or in
vitro (CTL activity) and preserved GVL activity to P815 tumor
cells resulting in improved leukemia free survival compared to wt
BMT recipients. We conclude that disruption of the innate
immune response by targeting CD14:LPS interactions signiﬁcantly
reduces GVHD and preserves donor T cell responses and GVL
effects. These data suggest that novel strategies which target this
receptor:ligand interaction may help prevent GVHD without sup-
pressing immune reconstitution and GVL activity after allo BMT.
